Table 2.
Patient | Age |
Menopausal statusComorbiditiesPerformance statusExpectations and preferencesToxicities to previous treatmentsAdherence, compliance | |
Tumor | Histological subtypeExpression of hormone receptorsHER2 amplificationIntrinsic subtypePredictive biomarkers * |
Disease | Site of metastasisTumor burdenSymptomatology and/or need for rapid responsePrevious endocrine treatmentDisease-free interval on adjuvant settingResponse to previous ETDuration of response to previous ET |
Agent | Mechanism of actionExpected toxicitiesPharmacological interactionsAvailabilityCostRoute of administration |
Other issues | Availability of clinical researchExisting guidelinesFinancial hardshipSocial support |
Predictive biomarkers for endocrine therapy in HR+ ABC are not available and developments in this field should be a priority of future research.
ABC, advanced breast cancer; ET, endocrine therapy; HER2, human epidermal growth factor receptor type 2; HR+, hormone receptor positive.